TY - JOUR TI - Extracellular vesicles as candidate mediators linking insulin resistance and metabolic dysfunction-associated steatotic liver disease AU - Hammad, Muhammad AU - Fardoos, Sadaf AU - Shakoor, Khadija AU - Shakoor, Abdul PY - 2026 JO - Exploration of Endocrine and Metabolic Diseases VL - 3 SP - 101486 DO - 10.37349/eemd.2026.101486 UR - https://www.explorationpub.com/Journals/eemd/Article/101486 AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder worldwide, with insulin resistance representing a central pathogenic determinant. Extracellular vesicles (EVs) have emerged as potential mediators of inter-organ communication that may help explain the tissue-specific metabolic reprogramming underlying MASLD. This narrative review synthesized experimental, translational, and clinical evidence examining EV involvement in the bidirectional relationship between insulin resistance and MASLD, prioritizing mechanistic studies with gain- or loss-of-function designs and corroborative human data. Experimental evidence indicates that adipose- and macrophage-derived EVs can promote systemic insulin resistance, whereas lipotoxic hepatocyte-derived EVs may propagate hepatic inflammation and fibrogenesis through bioactive lipids, proteins, and microRNAs. Conversely, selected immune-derived EVs exhibit hepatoprotective effects, highlighting context-dependent signalling. Vesicular routes proposed to link the steatotic liver with the vasculature, the endocrine pancreas, and the spleen are examined alongside the hepatic evidence, since cardiovascular disease is the principal cause of death in this population and type 2 diabetes is reciprocally related to hepatic steatosis. Human studies associate circulating EV profiles with disease severity and clinical outcomes. Collectively, EVs may constitute an important mechanistic link between insulin resistance and MASLD, although causal human evidence remains limited and methodological heterogeneity, lipoprotein contamination, and unresolved cargo stoichiometry continue to impede clinical translation. Reliance on rodent models, supraphysiological vesicle dosing, and interspecies differences in microRNA repertoire constitute further constraints upon translation. ER -